INVESTMENT SECURITIES

6 Months Ended

Dec. 31, 2021

Schedule of Investments [Abstract]

INVESTMENT SECURITIES

NOTE 6. INVESTMENT SECURITIES

On March 11, 2021 the Company was paid 6,500 common shares of Oncology Pharma, Inc. pursuant to an agreement entered into by and between the Company and Oncology Pharma, Inc. whereby the Company granted Oncology Pharma, Inc. an exclusive worldwide right and license for the development and commercialization of certain intellectual property controlled by the Company.

On December 31, 2021 the Company revalued 6,500 common shares of Oncology Pharma, Inc. at the closing price of the common shares on the OTC Pink market.

As of December 31, 2021:

	Schedule Of Common Shares
6,500 Common Shares of Oncology Pharma, Inc.
	Basis		Fair Value		Total Unrealized Losses			Net Unrealized Gain or (Loss) realized during the Quarter ended December 31,2021
$	177,450	$	26,325	$	(151125	)	$	(44,005)